Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
3,4-diaminopyridine (3,4-DAP) decreases symptoms of weakness in patients with LEMS, and
therefore can be used to decrease the amount of immune modulation therapy needed to provide
an equivalent degree of disease control.
Expanded Access
N/A
Kerry H Levin, M.D.
Principal Investigator
The Cleveland Clinic
United States: Food and Drug Administration
102,384
NCT01373333
September 1997
Name | Location |
---|---|
Cleveland Clinic Foundation | Cleveland, Ohio 44195 |